Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 160 participants.
Also called NCT06417489
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 160 participants
- Registry
-
NCT06417489
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06417489. Randomized; no masking; primary purpose treatment. Start 2024-05-31 (anticipated); primary completion 2026-05-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluation of Efficacy and Safety of Combination Therapy of Henagliflozin Proline, Retagliptin and Metformin in New Diagnosed Type 2 Diabetes Patients
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Combination therapy
- Intervention (Drug)
- Sequential treatment group
- Lead sponsor
- Peking University First Hospital
Record details
- Record id
cardio:ct-nct06417489- Content hash
7ecf55fedc42f437c142bdf1bc911705166b065e88bb855775b424a1ebd2bf59